202 related articles for article (PubMed ID: 19763356)
1. Development of a plasma- and albumin-free recombinant von Willebrand factor.
Turecek PL; Mitterer A; Matthiessen HP; Gritsch H; Varadi K; Siekmann J; Schnecker K; Plaimauer B; Kaliwoda M; Purtscher M; Woehrer W; Mundt W; Muchitsch EM; Suiter T; Ewenstein B; Ehrlich HJ; Schwarz HP
Hamostaseologie; 2009 Oct; 29 Suppl 1():S32-8. PubMed ID: 19763356
[TBL] [Abstract][Full Text] [Related]
2. Structure and function of a recombinant von Willebrand factor drug candidate.
Turecek PL; Schrenk G; Rottensteiner H; Varadi K; Bevers E; Lenting P; Ilk N; Sleytr UB; Ehrlich HJ; Schwarz HP
Semin Thromb Hemost; 2010 Jul; 36(5):510-21. PubMed ID: 20635317
[TBL] [Abstract][Full Text] [Related]
3. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease.
Schwarz HP; Schlokat U; Mitterer A; Váradi K; Gritsch H; Muchitsch EM; Auer W; Pichler L; Dorner F; Turecek PL
Semin Thromb Hemost; 2002 Apr; 28(2):215-26. PubMed ID: 11992244
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Wien Klin Wochenschr; 1999 Mar; 111(5):181-91. PubMed ID: 10226348
[TBL] [Abstract][Full Text] [Related]
5. Recombinant von Willebrand factor: preclinical development.
Plaimauer B; Schlokat U; Turecek PL; Mitterer A; Mundt W; Auer W; Pichler L; Gritsch H; Schwarz HP
Semin Thromb Hemost; 2001 Aug; 27(4):395-403. PubMed ID: 11547362
[TBL] [Abstract][Full Text] [Related]
6. Role of factor VIII-von Willebrand factor and fibronectin in the interaction of platelets in flowing blood with monomeric and fibrillar human collagen types I and III.
Houdijk WP; Sakariassen KS; Nievelstein PF; Sixma JJ
J Clin Invest; 1985 Feb; 75(2):531-40. PubMed ID: 3919060
[TBL] [Abstract][Full Text] [Related]
7. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
[TBL] [Abstract][Full Text] [Related]
8. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.
Turecek PL; Gritsch H; Pichler L; Auer W; Fischer B; Mitterer A; Mundt W; Schlokat U; Dorner F; Brinkman HJ; van Mourik JA; Schwarz HP
Blood; 1997 Nov; 90(9):3555-67. PubMed ID: 9345039
[TBL] [Abstract][Full Text] [Related]
9. Optimisation of the Factor VIII yield in mammalian cell cultures by reducing the membrane bound fraction.
Kolind MP; Nørby PL; Berchtold MW; Johnsen LB
J Biotechnol; 2011 Feb; 151(4):357-62. PubMed ID: 21219947
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
Morfini M; Mannucci PM; Tenconi PM; Longo G; Mazzucconi MG; Rodeghiero F; Ciavarella N; De Rosa V; Arter A
Thromb Haemost; 1993 Aug; 70(2):270-2. PubMed ID: 8236134
[TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions.
Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V
Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
Gill JC; Castaman G; Windyga J; Kouides P; Ragni M; Leebeek FW; Obermann-Slupetzky O; Chapman M; Fritsch S; Pavlova BG; Presch I; Ewenstein B
Blood; 2015 Oct; 126(17):2038-46. PubMed ID: 26239086
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
[TBL] [Abstract][Full Text] [Related]
15. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
de Romeuf C; Hilbert L; Mazurier C
Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of recombinant von Willebrand factor in a canine model of von Willebrand disease.
Schwarz HP; Dorner F; Mitterer A; Mundt W; Schlokat U; Pichler L; Turecek PL
Haemophilia; 1998; 4 Suppl 3():53-62. PubMed ID: 10028320
[TBL] [Abstract][Full Text] [Related]
17. Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector.
Meulien P; Nishino M; Mazurier C; Dott K; Piétu G; Jorieux S; Pavirani A; Girma JP; Oufkir D; Courtney M
Thromb Haemost; 1992 Jan; 67(1):154-60. PubMed ID: 1615470
[TBL] [Abstract][Full Text] [Related]
18. Comparison of plasma-derived and recombinant von Willebrand factor by atomic force microscopy.
Seyfried BK; Friedbacher G; Rottensteiner H; Schwarz HP; Ehrlich H; Allmaier G; Turecek PL
Thromb Haemost; 2010 Sep; 104(3):523-30. PubMed ID: 20589314
[TBL] [Abstract][Full Text] [Related]
19. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide.
Hilbert L; Nurden P; Caron C; Nurden AT; Goudemand J; Meyer D; Fressinaud E; Mazurier C;
Thromb Haemost; 2006 Sep; 96(3):290-4. PubMed ID: 16953269
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease.
Weiss HJ; Pietu G; Rabinowitz R; Girma JP; Rogers J; Meyer D
J Lab Clin Med; 1983 Mar; 101(3):411-25. PubMed ID: 6186757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
